Trades and observations from a British contrarian stock investor

This blog is not intended to give financial advice. Before investing, do your own research and consult your financial adviser if appropriate. The accuracy of any information included is not guaranteed and may be subject to conjecture or interpretation by Contrarian Investor. Therefore visitors should validate all facts using alternative sources where possible.

Friday, April 30, 2010

Rodman and Renshaw put 300p target on GW Pharma

Broker Rodman and Renshaw have initiated coverage of GW Pharma (GWP) with a Market Outperform rating and a 300p 12 month target against the current share price of 122p.

They estimate GW to be profitable in 2012 and estimate the company to earn £0.40/share in 2014. Applying a 20X multiple and a 30% annual discount rate they derive a 12-month target price of £3/share (300p).

This moved the share price up 10% yesterday to close at 127p. Profit takers have moved in today and Contrarian Investor UK took the opportunity to top slice the holding with major news not due for a couple weeks yet and the key date being the interim results on May 18th. The shares are currently down 8.5p or 7% to 121p.
Posted by Contrarian Investor UK at 3:12 PM
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)